Appoints Laika Consulting for IR and PR support
Saniona, a leading biotech company in the field of ion channels, today announces that it has appointed Laika Consulting as its Swedish corporate and investor communication consultancy.
Laika Consulting will provide IR and PR support from their offices in Sweden. The support is part of the professionalization of Saniona in order to make the company ready to be listed on Nasdaq OMX Stockholm and it includes among other things:
- PR work to bring news about Saniona’s products and general development.
- Distribution of articles about Saniona through Laika’s digital communication channels including Investerarbrevet.se, one of Sweden's largest newsletters that reaches 700,000 investors each month.
- News and analysis service through BioStock (www.biostock.se). BioStock is a news channel focusing on presenting Nordic Life Science companies, based on journalistic material and other public available information. BioStock will with a journalistic approach follow and analyse Saniona.
- Newsletter with news from Saniona and news in the field of research and the industry that Saniona is active in. The newsletter will be distributed in the form of an e-mail to interested shareholders and other stakeholders.
Investors and other stakeholders may subscribe for Saniona’s Newsletter and Investerarbrevet.se by using the following link.
The above links for subscription may also be found at Saniona’s homepage, www.saniona.com.
“We are proud to announce Saniona as one of our clients. We are impressed by their work and Saniona is in a very exciting stage at the moment. We have absolute confidence that together we can attract great interest both from investors and other stakeholders, and prepare Saniona for a listing on Nasdaq Stockholm,“ says Ingmar Rentzhog, CEO of Laika Consulting.
“Laika’s experienced team will provide Saniona with guidance as it raises the profile of the company and broadens the investor contact base amongst retail investors, institutional investors, private client brokers and wealth managers. We attach high importance to our communication with all audiences, notably investors. The appointment of Laika reflects our ambition of listing the company at Nasdaq Stockholm SmallCap later this year,” says Thomas Feldthus, EVP and CFO of Saniona.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: email@example.com
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at AktieTorget since April 2014 and has about 3,000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.